
Global In-Vitro Colorectal Cancer Screening Tests Market Report and Forecast 2024-2032
Description
Global In-Vitro Colorectal Cancer Screening Tests Market Report and Forecast 2024-2032
Global In Vitro Colorectal Cancer Screening Tests Market Report and Forecast 2024-2032
The global in-vitro colorectal cancer screening tests market size was valued at USD 920.4 million in 2023, driven by the rising prevalence of colorectal cancer across the globe. The market is expected to grow at a CAGR of 5.53% during the forecast period of 2024-2032, likely to attain a value of USD 1492.8 million by 2032.
Global In Vitro Colorectal Cancer Screening Tests Market Analysis
From 2017 to 2022, the market experienced considerable growth, fueled by rising global awareness of the importance of early colorectal cancer detection and the effectiveness of screening in reducing mortality. The adoption of various in vitro diagnostic tests, such as fecal occult blood tests (FOBT), fecal immunochemical tests (FIT), and DNA-based tests, increased significantly during this timeframe. This growth trajectory was supported by government initiatives aimed at implementing widespread screening programs. Despite this positive trend, the market faced challenges, including the high costs associated with the latest diagnostic tests and a lack of healthcare infrastructure in several regions, which limited access to screening services.
Global In Vitro Colorectal Cancer Screening Tests Market Trends
The market for in vitro colorectal cancer (CRC) screening tests has undergone significant transformations from 2017 to 2032, driven by advancements in diagnostic technologies, increasing awareness about colorectal cancer prevention, and changes in screening guidelines. These factors have collectively influenced the development, demand, and deployment of in vitro CRC screening tests worldwide. Below are the key trends observed in this market over the specified period.
- Technological Advancements in Screening Tests
- Shift Towards Non-invasive Screening Options
- Increasing Awareness and Screening Guidelines
- Growth in Molecular Diagnostics and Personalized Medicine
- Expansion in Emerging Markets
- Regulatory and Reimbursement Landscape
- Increased Focus on Integrated Screening Programs
Global In Vitro Colorectal Cancer Screening Tests Market Segmentation
Market Breakup by Test Type
- Fecal Occult Blood Test (FOBT)
- Guaiac FOBT
- Immuno-FOBT (FIT)
- Stool DNA Test (sDNA)
- Colonoscopy
- Flexible Sigmoidoscopy
- CT Colonography (Virtual Colonoscopy)
- Biomarker Tests
- CEA Tests
- Other Blood-Based Tests
Market Breakup by Technology
- Tumor Biomarker-Based Tests
- Guaiac-Based Tests
- Immuno-FOBT (FIT)
- DNA-Based Tests
- Colonoscopy Technology
- Other Emerging Technologies
Market Breakup by Collection Method
- Guaiac Sampling
- Immuno-FOBT Sampling
- Stool DNA Sampling
- Blood Sampling (for Biomarker Tests)
- Others
Market Breakup by End User
- Hospitals
- Diagnostic Laboratories
- Ambulatory Surgical Centers
- Research Institutes
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global In Vitro Colorectal Cancer Screening Tests Market: Competitive Landscape
The in vitro colorectal cancer screening tests market is highly competitive and fragmented, with the presence of several global and regional players. The key players are engaged in product development, innovation, mergers and acquisitions, and expansion strategies to gain a larger share of the market. Some of the prominent players operating in this market are Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Beckman Coulter, Inc. (a Danaher Company), Biohit Oyj, Epigenomics AG, Exact Sciences Corporation, Hemosure, Inc., Randox Laboratories Ltd., QIAGEN N.V., Eiken Chemical Co., Ltd., Novigenix SA, Sysmex Corporation, Immundiagnostik AG, and Epi proColon (Epigenomics AG). These companies offer a variety of products, such as fecal immunochemical tests, fecal occult blood tests, stool DNA tests, and blood-based tests, for the detection and diagnosis of colorectal cancer.
Key Questions Answered in This Report
- How has the in vitro colorectal cancer screening tests market performed so far, and how will it perform in the coming years?
- What are the major drivers and opportunities in the in vitro colorectal cancer screening tests market?
- What is the impact of each driver, restraint, and opportunity in the market?
- What are the key regional markets for in vitro colorectal cancer screening tests?
- What is the impact of rising awareness of colorectal cancers on market expansion?
- What are the most dominant markets?
- What is the breakup of the market based on the test type?
- Which invasive technology provides a better visual analysis of such cancers to remove polyps?
- What is the breakup of the market based on the collection method?
- How is the market organized in terms of competition?
- Which companies are leading the in vitro colorectal cancer screening tests market?
- The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the in vitro colorectal cancer screening tests market from 2017-2032.
- The research report provides the latest information on the market drivers, challenges, and opportunities in the global in vitro colorectal cancer screening tests market.
- The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
- Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the in vitro colorectal cancer screening tests industry and its attractiveness.
- The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global In-Vitro Colorectal Cancer Screening Tests Market Overview
- 3.1 Global In-Vitro Colorectal Cancer Screening Tests Market Historical Value (2017-2023)
- 3.2 Global In-Vitro Colorectal Cancer Screening Tests Market Forecast Value (2024-2032)
- 4 Global In-Vitro Colorectal Cancer Screening Tests Market Landscape*
- 4.1 Global In-Vitro Colorectal Cancer Screening Tests: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global In-Vitro Colorectal Cancer Screening Tests: Product Landscape
- 4.2.1 Analysis by Test Type
- 4.2.2 Analysis by Technology
- 5 Global In-Vitro Colorectal Cancer Screening Tests Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global In-Vitro Colorectal Cancer Screening Tests Market Segmentation (2017-2032)
- 6.1 Global In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Test Type
- 6.1.1 Market Overview
- 6.1.2 Fecal Occult Blood Test (FOBT)
- 6.1.2.1 Guaiac FOBT
- 6.1.2.2 Immuno-FOBT (FIT)
- 6.1.3 Stool DNA Test (sDNA)
- 6.1.4 Colonoscopy
- 6.1.5 Flexible Sigmoidoscopy
- 6.1.6 CT Colonography (Virtual Colonoscopy)
- 6.1.7 Biomarker Tests
- 6.1.7.1 CEA Tests
- 6.1.7.2 Other Blood-Based Tests
- 6.2 Global In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Technology
- 6.2.1 Market Overview
- 6.2.2 Tumor Biomarker-Based Tests
- 6.2.3 Guaiac-Based Tests
- 6.2.4 Immuno-FOBT (FIT)
- 6.2.5 DNA-Based Tests
- 6.2.6 Colonoscopy Technology
- 6.2.7 Other Emerging Technologies
- 6.3 Global In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Collection Method
- 6.3.1 Market Overview
- 6.3.2 Guaiac Sampling
- 6.3.3 Immuno-FOBT Sampling
- 6.3.4 Stool DNA Sampling
- 6.3.5 Blood Sampling (for Biomarker Tests)
- 6.3.6 Others
- 6.4 Global In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by End User
- 6.4.1 Market Overview
- 6.4.2 Hospitals
- 6.4.3 Diagnostic Laboratories
- 6.4.4 Ambulatory Surgical Centers
- 6.4.5 Research Institutes
- 6.4.6 Others
- 6.5 Global In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Region
- 6.5.1 Market Overview
- 6.5.2 North America
- 6.5.3 Europe
- 6.5.4 Asia Pacific
- 6.5.5 Latin America
- 6.5.6 Middle East and Africa
- 7 North America In-Vitro Colorectal Cancer Screening Tests Market (2017-2032)
- 7.1 North America In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Test Type
- 7.1.1 Market Overview
- 7.1.2 Fecal Occult Blood Test (FOBT)
- 7.1.2.1 Guaiac FOBT
- 7.1.2.2 Immuno-FOBT (FIT)
- 7.1.3 Stool DNA Test (sDNA)
- 7.1.4 Colonoscopy
- 7.1.5 Flexible Sigmoidoscopy
- 7.1.6 CT Colonography (Virtual Colonoscopy)
- 7.1.7 Biomarker Tests
- 7.1.7.1 CEA Tests
- 7.1.7.2 Other Blood-Based Tests
- 7.2 North America In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Technology
- 7.2.1 Market Overview
- 7.2.2 Tumor Biomarker-Based Tests
- 7.2.3 Guaiac-Based Tests
- 7.2.4 Immuno-FOBT (FIT)
- 7.2.5 DNA-Based Tests
- 7.2.6 Colonoscopy Technology
- 7.2.7 Other Emerging Technologies
- 7.3 North America In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Country
- 7.3.1 United States of America
- 7.3.2 Canada
- 8 Europe In-Vitro Colorectal Cancer Screening Tests Market (2017-2032)
- 8.1 Europe In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Test Type
- 8.1.1 Market Overview
- 8.1.2 Fecal Occult Blood Test (FOBT)
- 8.1.2.1 Guaiac FOBT
- 8.1.2.2 Immuno-FOBT (FIT)
- 8.1.3 Stool DNA Test (sDNA)
- 8.1.4 Colonoscopy
- 8.1.5 Flexible Sigmoidoscopy
- 8.1.6 CT Colonography (Virtual Colonoscopy)
- 8.1.7 Biomarker Tests
- 8.1.7.1 CEA Tests
- 8.1.7.2 Other Blood-Based Tests
- 8.2 Europe In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Technology
- 8.2.1 Market Overview
- 8.2.2 Tumor Biomarker-Based Tests
- 8.2.3 Guaiac-Based Tests
- 8.2.4 Immuno-FOBT (FIT)
- 8.2.5 DNA-Based Tests
- 8.2.6 Colonoscopy Technology
- 8.2.7 Other Emerging Technologies
- 8.3 Europe In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Country
- 8.3.1 United Kingdom
- 8.3.2 Germany
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Others
- 9 Asia Pacific In-Vitro Colorectal Cancer Screening Tests Market (2017-2032)
- 9.1 Asia Pacific In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Test Type
- 9.1.1 Market Overview
- 9.1.2 Fecal Occult Blood Test (FOBT)
- 9.1.2.1 Guaiac FOBT
- 9.1.2.2 Immuno-FOBT (FIT)
- 9.1.3 Stool DNA Test (sDNA)
- 9.1.4 Colonoscopy
- 9.1.5 Flexible Sigmoidoscopy
- 9.1.6 CT Colonography (Virtual Colonoscopy)
- 9.1.7 Biomarker Tests
- 9.1.7.1 CEA Tests
- 9.1.7.2 Other Blood-Based Tests
- 9.2 Asia Pacific In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Technology
- 9.2.1 Market Overview
- 9.2.2 Tumor Biomarker-Based Tests
- 9.2.3 Guaiac-Based Tests
- 9.2.4 Immuno-FOBT (FIT)
- 9.2.5 DNA-Based Tests
- 9.2.6 Colonoscopy Technology
- 9.2.7 Other Emerging Technologies
- 9.3 Asia Pacific In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Country
- 9.3.1 China
- 9.3.2 Japan
- 9.3.3 India
- 9.3.4 ASEAN
- 9.3.5 Australia
- 9.3.6 Others
- 10 Latin America In-Vitro Colorectal Cancer Screening Tests Market (2017-2032)
- 10.1 Latin America In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Test Type
- 10.1.1 Market Overview
- 10.1.2 Fecal Occult Blood Test (FOBT)
- 10.1.2.1 Guaiac FOBT
- 10.1.2.2 Immuno-FOBT (FIT)
- 10.1.3 Stool DNA Test (sDNA)
- 10.1.4 Colonoscopy
- 10.1.5 Flexible Sigmoidoscopy
- 10.1.6 CT Colonography (Virtual Colonoscopy)
- 10.1.7 Biomarker Tests
- 10.1.7.1 CEA Tests
- 10.1.7.2 Other Blood-Based Tests
- 10.2 Latin America In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Technology
- 10.2.1 Market Overview
- 10.2.2 Tumor Biomarker-Based Tests
- 10.2.3 Guaiac-Based Tests
- 10.2.4 Immuno-FOBT (FIT)
- 10.2.5 DNA-Based Tests
- 10.2.6 Colonoscopy Technology
- 10.2.7 Other Emerging Technologies
- 10.3 Latin America In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Country
- 10.3.1 Brazil
- 10.3.2 Argentina
- 10.3.3 Mexico
- 10.3.4 Others
- 11 Middle East and Africa In-Vitro Colorectal Cancer Screening Tests Market (2017-2032)
- 11.1 Middle East and Africa In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Test Type
- 11.1.1 Market Overview
- 11.1.2 Fecal Occult Blood Test (FOBT)
- 11.1.2.1 Guaiac FOBT
- 11.1.2.2 Immuno-FOBT (FIT)
- 11.1.3 Stool DNA Test (sDNA)
- 11.1.4 Colonoscopy
- 11.1.5 Flexible Sigmoidoscopy
- 11.1.6 CT Colonography (Virtual Colonoscopy)
- 11.1.7 Biomarker Tests
- 11.1.7.1 CEA Tests
- 11.1.7.2 Other Blood-Based Tests
- 11.2 Middle East and Africa In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Technology
- 11.2.1 Market Overview
- 11.2.2 Tumor Biomarker-Based Tests
- 11.2.3 Guaiac-Based Tests
- 11.2.4 Immuno-FOBT (FIT)
- 11.2.5 DNA-Based Tests
- 11.2.6 Colonoscopy Technology
- 11.2.7 Other Emerging Technologies
- 11.3 Middle East and Africa In-Vitro Colorectal Cancer Screening Tests Market (2017-2032) by Country
- 11.3.1 Saudi Arabia
- 11.3.2 United Arab Emirates
- 11.3.3 Nigeria
- 11.3.4 South Africa
- 11.3.5 Others
- 12 Regulatory Framework
- 12.1 Regulatory Overview
- 12.1.1 US FDA
- 12.1.2 EU EMA
- 12.1.3 INDIA CDSCO
- 12.1.4 JAPAN PMDA
- 12.1.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication Year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
- 14.1 Analysis by Year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by Departments
- 14.7 Analysis by Recipient Organization
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Supplier Landscape
- 17.1 Abbott Laboratories
- 17.1.1 Financial Analysis
- 17.1.2 Product Portfolio
- 17.1.3 Demographic Reach and Achievements
- 17.1.4 Mergers and Acquisitions
- 17.1.5 Certifications
- 17.2 F. Hoffmann-La Roche Ltd.
- 17.2.1 Financial Analysis
- 17.2.2 Product Portfolio
- 17.2.3 Demographic Reach and Achievements
- 17.2.4 Mergers and Acquisitions
- 17.2.5 Certifications
- 17.3 Siemens Healthineers AG
- 17.3.1 Financial Analysis
- 17.3.2 Product Portfolio
- 17.3.3 Demographic Reach and Achievements
- 17.3.4 Mergers and Acquisitions
- 17.3.5 Certifications
- 17.4 Beckman Coulter, Inc. (a Danaher Company)
- 17.4.1 Financial Analysis
- 17.4.2 Product Portfolio
- 17.4.3 Demographic Reach and Achievements
- 17.4.4 Mergers and Acquisitions
- 17.4.5 Certifications
- 17.5 Biohit Oyj
- 17.5.1 Financial Analysis
- 17.5.2 Product Portfolio
- 17.5.3 Demographic Reach and Achievements
- 17.5.4 Mergers and Acquisitions
- 17.5.5 Certifications
- 17.6 Epigenomics AG
- 17.6.1 Financial Analysis
- 17.6.2 Product Portfolio
- 17.6.3 Demographic Reach and Achievements
- 17.6.4 Mergers and Acquisitions
- 17.6.5 Certifications
- 17.7 Exact Sciences Corporation
- 17.7.1 Financial Analysis
- 17.7.2 Product Portfolio
- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisitions
- 17.7.5 Certifications
- 17.8 Hemosure, Inc.
- 17.8.1 Financial Analysis
- 17.8.2 Product Portfolio
- 17.8.3 Demographic Reach and Achievements
- 17.8.4 Mergers and Acquisitions
- 17.8.5 Certifications
- 17.9 Randox Laboratories Ltd.
- 17.9.1 Financial Analysis
- 17.9.2 Product Portfolio
- 17.9.3 Demographic Reach and Achievements
- 17.9.4 Mergers and Acquisitions
- 17.9.5 Certifications
- 17.10 QIAGEN N.V.
- 17.10.1 Financial Analysis
- 17.10.2 Product Portfolio
- 17.10.3 Demographic Reach and Achievements
- 17.10.4 Mergers and Acquisitions
- 17.10.5 Certifications
- 17.11 Eiken Chemical Co., Ltd.
- 17.11.1 Financial Analysis
- 17.11.2 Product Portfolio
- 17.11.3 Demographic Reach and Achievements
- 17.11.4 Mergers and Acquisitions
- 17.11.5 Certifications
- 17.12 Novigenix SA
- 17.12.1 Financial Analysis
- 17.12.2 Product Portfolio
- 17.12.3 Demographic Reach and Achievements
- 17.12.4 Mergers and Acquisitions
- 17.12.5 Certifications
- 17.13 Sysmex Corporation
- 17.13.1 Financial Analysis
- 17.13.2 Product Portfolio
- 17.13.3 Demographic Reach and Achievements
- 17.13.4 Mergers and Acquisitions
- 17.13.5 Certifications
- 17.14 Immundiagnostik AG
- 17.14.1 Financial Analysis
- 17.14.2 Product Portfolio
- 17.14.3 Demographic Reach and Achievements
- 17.14.4 Mergers and Acquisitions
- 17.14.5 Certifications
- 17.15 Epi proColon (Epigenomics AG)
- 17.15.1 Financial Analysis
- 17.15.2 Product Portfolio
- 17.15.3 Demographic Reach and Achievements
- 17.15.4 Mergers and Acquisitions
- 17.15.5 Certifications
- List not exhaustive
- 18 Global In-Vitro Colorectal Cancer Screening Tests Market – Distribution Model (Additional Insight)
- 18.1 Overview
- 18.2 Potential Distributors
- 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.